Loading stock data…
$67.42+0.61 (+0.92%)
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.
Vaxcyte, Inc. in the Healthcare sector is trading at $68.37 with a market capitalization of $8.8B. Wall Street consensus targets $117.30 (10 analysts), implying a +71.6% move over the next 12 months. The stock is currently 25% below its 52-week high of $90.75, remaining 22.0% above its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$302.78M↑ | -$345.85M↓ | -$274.28M↓ | -$242.38M↓ | -$226.22M |
| Net Income | -$284.30M↑ | -$320.62M↓ | -$246.51M↓ | -$212.83M↓ | -$166.57M |
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococca...